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Abstract
Barely a decade after the discovery of the gene encoding proprotein convertase subtilisin/kexin type 9 (PCSK9) and
its recognition as a key player in cholesterol metabolism, PCSK9 inhibition is now considered an exciting approach
in the reduction of residual risk of cardiovascular disease. The progress from PCSK9 discovery to the development
of targeted treatment has been unprecedented in terms of scale and speed. The first suggestion of a link between
PCSK9 and hypercholesterolemia was published in 2003; a decade later, two meta-analyses of clinical trials comparing
anti-PCSK9 treatment to placebo or ezetimibe, including >10,000 hypercholesterolemic individuals, were published.
Currently, three PCSK9 inhibitors are being evaluated in clinical outcome trials and the results will determine the future
of these lipid-lowering therapies by establishing their clinical efficacy in terms of cardiovascular event reduction, safety,
and the consequences of prolonged exposure to very low levels of LDL-cholesterol. Irrespective of their outcomes, the
exceptionally rapid development of these drugs exemplifies how novel technologies, genetic validation, and rapid
clinical progression provide the tools to expedite the development of new drugs.
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Background
Two decades after the results of the Scandinavian
Simvastatin Survival Study first showed that statins ef-
fectively improve survival in patients with cardiovascular
disease (CVD), thus initiating a revolution in the treat-
ment of dyslipidemia [1], ezetimibe has been the only
drug shown to further improve outcomes for dyslipid-
emic patients [2]. Research programs of novel com-
pounds were prematurely halted due to safety concerns
or a lack of efficacy and the use of such drugs was often
associated with only modest reductions in low-density
lipoprotein cholesterol (LDL-C) [3–6]. Established lipid-
modifying compounds, such as fibrates and nicotinic
acids, failed to improve CVD events as the primary
outcome when used in conjunction with optimal statin
therapy [7, 8]. Therefore, recent guidelines no longer
recommend the routine use of non-statin drugs in con-
junction with high-intensity statin treatment [9]. Never-
theless, many patients fail to achieve acceptable lipid
control with or are unable to tolerate statin treatment
[10, 11]. Additionally, consideration of the potential
merits of further LDL-C reductions resurfaced when the
results of the IMProved Reduction of Outcomes: Vytorin
Efficacy International Trial (IMPROVE-IT) study indi-
cated that addition of ezetimibe to simvastatin signifi-
cantly reduced the risk of subsequent CVD events in
patients with acute coronary syndromes [2]. Given these
considerations and since the discovery of the association
between mutations in proprotein convertase subtilisin/
kexin type 9 (PCSK9) and familial hypercholesterolemia
(FH) in 2003 [12], PCSK9 inhibitors have emerged as
the prime candidate to further improve outcomes for
CVD patients and may initiate the next revolution in
anti-atherosclerotic therapy.
Discovery and function
PCSK9 was recognized to play an important role in
LDL-C metabolism after the identification of gain-of-
function mutations in two French families with FH
without mutations in other FH-associated genes [12].
Subsequent experiments revealed that PCSK9 increases
levels of LDL-C by reducing the available pool of hepatic
LDL-receptors [13]. In the absence of PCSK9, the LDL-
receptor is recycled back to the plasma membrane. Bind-
ing of PCSK9, on the other hand, prevents LDL-receptor
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recycling and instead targets it for lysosomal degradation
(Fig. 1a) [13]. An extensive review of the underlying mech-
anisms of PCSK9 inhibition was recently provided by
Lambert et al. [13]. Large cohort studies have revealed as-
sociations between variations in the PCSK9 gene and
LDL-C levels and CVD risk [14]. In addition, studies have
shown that statin treatment increases PCSK9 levels [13].
The inverse relation between PCSK9 activity levels and
LDL-receptors suggests that PCSK9 inhibition could have
a synergistic effect with statins on LDL-C. Therefore,
PCSK9 has been identified as a promising target for anti-
atherosclerotic drug development. Several strategies have
been developed to reduce PCSK9 function, including
binding of plasma PCSK9 by monoclonal antibodies,
reducing PCSK9 expression by silencing RNA, or vaccin-
ation against PCSK9 [15, 16]. The present review focuses
primarily on PCSK9-inhibiting antibodies due to their
presently more advanced clinical development.
Development of PCSK9-inhibiting antibodies
The first reports of phase I studies of three PCSK9-
inhibiting antibodies, the mechanism of action of which
is shown in Fig. 1b, were published a mere decade after
the discovery of PCSK9. In their landmark study, Stein
et al. [17] demonstrated the ability of the PCSK9-
inhibiting antibody alirocumab to reduce LDL-C by
more than 60 % in both healthy volunteers and patients
with FH. Subsequent phase I studies of other PCSK9
Fig. 1 a. PCSK9-mediated degradation of low-density lipoprotein receptor (LDLR). A complex of low-density lipoprotein cholesterol (LDL-C), LDLR,
and PCSK9 is internalized into hepatocytes within clathrin-coated pits and subsequently undergoes lysosomal degradation. b. PCSK9 inhibition.
Monoclonal antibodies bound to PCSK9 prevent the association between PCSK9 and LDLR. LDLR binds and internalizes LDL-C particles, which are
then degraded in the lysosome, whereas the LDLR is recycled back to the plasma membrane. Re-use kindly permitted by the American Society
for Biochemistry and Molecular Biology, Inc. Figure derived from The PCSK9 decade [13]
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inhibitors, including evolocumab and bococizumab, con-
firmed these findings [18]. Hitherto, the clinical potential
of PCSK9 inhibition with monoclonal antibodies has
been studied in more than 20 short-term clinical trials
against various background lipid-lowering therapies and
with both placebo and ezetimibe as a comparator treat-
ment. The populations reflected the major categories of
patients for whom PCSK9 inhibition will likely be used
in practice: familial- and non-familial hypercholesterol-
emia, statin-intolerant patients, and high-risk secondary
prevention patients who fail to achieve acceptable lipid
goals with currently available treatment options.
Effect of PCSK9-inhibiting antibodies
Two recent meta-analyses evaluated the clinical potential
of antibody PCSK9 inhibition in >10,000 patients who
participated in over 20 phase II and III trials [19, 20].
These meta-analyses included data from most of the avail-
able studies with alirocumab and evolocumab. Not in-
cluded in the first meta-analysis were observations from
the Open-Label Study of Long-Term Evaluation against
LDL Cholesterol (OSLER), which was an open label exten-
sion study of participants who had completed phase II or
III studies (“parent trials”) of evolocumab [21]. The results
were, in essence, similar to those from the large dataset in
the meta-analyses [19]. In contrast to the substantial body
of evidence on alirocumab and evolocumab, longer-term
safety and efficacy data on bococizumab is relatively lim-
ited, with only one full publication on 351 patients avail-
able to date [22].
Effects on lipids
All trials confirmed the beneficial effect of PCSK9 inhib-
ition with evolocumab and alirocumab on LDL-C levels.
The use of PCSK9 monoclonal antibodies was associated
with mean LDL-C reductions of approximately 50 %
[19, 20]. These results persisted during follow-up, and
were similar across different doses, patient popula-
tions, and in patients with or without background sta-
tin therapy [19–21]. Compared to ezetimibe, PCSK9
inhibition resulted in a mean LDL-C reduction of ap-
proximately 36 % (95 % confidence interval (CI), 33–
39 %) [19]. In addition to their LDL-C lowering effect,
PCSK9 inhibitors consistently increased high-density lipo-
protein cholesterol by approximately 6 % (95 % CI, 6–
7 %) and lowered lipoprotein(a) by approximately 26 %
(95 % CI, 23–30 %) both in placebo- and ezetimibe-
controlled trials [19]. The effects on lipid levels were
similar in trials on evolocumab, alirocumab, and boco-
cizumab [19, 20, 22].
Clinical efficacy
The published individual trials were not powered to
study the efficacy in terms of clinical outcomes. In total,
10 randomized controlled trials, with over 5000 par-
ticipants, reported data on myocardial infarction [19].
One of the meta-analyses studied myocardial infarction
rates and showed a significantly lower rate (0.6 %; 19/3289
patients) in PCSK9 inhibitor-treated patients compared to
those who received no anti-PCSK9 treatment (1.0 %;
19/1906 patients; odds ratio, 0.49; 95 % CI, 0.26–
0.93) [19]. Similarly, statistically significant reductions
in CVD event rates were reported during the 1-year
follow-up of the OSLER and ODYSSEY long-term tri-
als [21, 23]. Furthermore, these preliminary analyses
suggest a statistically significant reduction in all-cause
mortality and a non-significant reduction in CVD mortal-
ity. Because of the limited number of events, long-term
clinical outcome studies should be awaited to substantiate
these findings.
Safety
Pooled analysis of serious adverse event rates from phase
II and III studies demonstrated similar incidence rates in
patients treated with PCSK9 inhibitors versus controls
[19]. Similarly, there were no differences in the incidence
of any adverse events compared to placebo, irrespective
of the dosage of evolocumab [20]. Moreover, adherence
rates were similar in both groups. Given that PCSK9 in-
hibitors could be a valuable option for statin-intolerant
patients, the observation that elevated creatine kinase
occurred less frequently in PCSK9 inhibitor-treated pa-
tients than in controls is of interest [19, 20]. None of the
phase III trials reported the presence of neutralizing
antibodies. The favorable safety profile of PCSK9 inhibi-
tors [24], as well as the results of several meta-analyses
of statin trials [25], provide reassuring evidence on the
short-term safety of achieving very low levels of LDL-C.
The observation of a slightly increased occurrence of
neurocognitive dysfunction in patients receiving alirocu-
mab or evolocumab in the ODYSSEY long-term trial
(1.2 % vs. 0.5 %; P = 0.17) [21] and OSLER trial (0.9 % vs.
0.2 %; P = 0.3) [23] has led to the initiation of a study
designed specifically to evaluate neurocognitive effects
of PCSK9 inhibition with evolocumab in 4000 individ-
uals (NCT Trial Identifier: NCT02207634). Further,
inherent to monoclonal antibodies is their subcutane-
ous administration. A prevalence of approximately
5 % of injection site reactions was reported by pa-
tients in the active treatment arms with evolocumab or
alirocumab [21, 23].
Future perspectives
The results of large ongoing clinical outcome trials of
PCSK9 inhibitors will determine the way forward in the
treatment of dyslipidemia since these trials will indicate
whether additional LDL-C lowering safely translates into
cardiovascular benefit. Although it would be premature
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to endorse these drugs for widespread use before the re-
sults of ongoing trials are available, it is interesting to
speculate on the categories of patients for whom PCSK9
inhibition would be first applied. Notably, the United
States Food and Drug Administration has recently ap-
proved alirocumab, in addition to diet and maximally
tolerated statins, in patients with heterozygous FH or
clinical CVD who require additional LDL-C lowering
[26]. Similarly, the European Medicines Agency has rec-
ommended approval of alirocumab and evolocumab for
patients who fail to achieve acceptable lipid control des-
pite optimal statin therapy, but also explicitly mentions
patients with homozygous FH and statin-intolerant pa-
tients [27, 28]. Arguably, the largest group of patients
who will potentially benefit from PCSK9 inhibition con-
sists of those remaining at increased risk of CVD despite
currently available lipid-lowering treatment due to, for
example, having a very high baseline CVD risk. Statin
treatment will likely remain the basis of lipid lowering
treatment in the foreseeable future due to their relatively
low costs, oral availability, and their established benefi-
cial safety profile and clinical efficacy. However, results
of the IMPROVE-IT study confirmed the ‘lower is better’
paradigm regarding LDL-C levels and CVD risk, demon-
strating additional clinical benefit through the addition
of ezetimibe to simvastatin [2]. Importantly, the risk
reduction associated with additional LDL-C lowering
appears to be independent of baseline LDL-C [2, 24].
Discussion on the potential role of PCSK9 inhibitors in
the treatment of this large and heterogeneous group of
patients will therefore focus on the desired balance be-
tween additional absolute risk reduction and costs. In
the IMPROVE-IT trial, addition of ezetimibe to simva-
statin resulted in an absolute risk reduction of 2 % in
CVD events after 7 years of treatment, or a number
needed to treat for 5 years of approximately 70 to pre-
vent one CVD event [2]. The number needed to treat
for the more potent PCSK9 inhibitors will likely be
three-fold lower [21, 23].
Another group of patients who may benefit from
PCSK9 inhibitors could be those with a strict indication
for lipid lowering but who are statin intolerant. Indeed,
this category of patients is included in the recent
European Medicines Agency recommendation [27]. Al-
though multiple definitions of statin intolerance exist,
the magnitude of the problem is illustrated by the obser-
vation that 75 % of patients discontinue statins within
2 years, with statin-associated muscle symptoms being
the prevailing reason in approximately 60 % of cases
[10, 29]. Evolocumab and alirocumab showed a good
safety and tolerability profile in statin-intolerant pa-
tients [30–32]; bococizumab is being tested in statin-
intolerant patients (NCT Trial Identifier: NCT02135029).
The potential of PCSK9 inhibitors as an alternative for
statin-intolerant patients who fail to achieve acceptable
LDL-C control on currently available therapies has been
recognized in the current European Atherosclerosis
Society guideline [33].
Furthermore, PCSK9 inhibition may be of benefit in
the treatment of patients with homozygous FH.
Currently available oral lipid-lowering agents do lower
LDL-C in most homozygous FH patients, but the limited
efficacy means that these patients are currently often
dependent on invasive treatment modalities such as
LDL-C apheresis or Apolipoprotein B or microsomal tri-
glyceride transfer protein inhibition, with the latter two
having been associated with steatosis [34–37]. Evolocu-
mab has been proven efficacious in reducing LDL-C in a
Table 1 Ongoing clinical outcome trials of PCSK9 inhibitors
Trial name Study drug Patient population Primary outcome measure Follow-up
FOURIERNCT01764633 Evolocumab n = 27,000; history of CVD – at
high risk of recurrent event;
LDL-C ≥70 mg/dL or non-HDL-C
≥100 mg/dL; background statin
therapy
Time to cardiovascular death, myocardial
infarction, hospitalization for unstable
angina, stroke, or coronary revascularization
5 years
ODYSSEY OUTCOMESNCT01663402 Alirocumab n = 18,000; acute coronary syndrome
<52 weeks earlier; LDL-C ≥70 mg/dL
or non-HDL-C ≥100 mg/dL;
background statin therapy
Time to cardiovascular death, non-fatal
myocardial infarction, hospitalization for
unstable angina, or stroke
64 months
SPIRE-1NCT01975376 Bococizumab n = 17,000; high risk of CVD event,
primary and secondary prevention;
background lipid-lowering treatment;
LDL-C 70–100 mg/dL or non-HDL-C
100–130 mg/dL
Time to composite major cardiovascular
event (cardiovascular death, non-fatal
myocardial infarction, non-fatal stroke,
and hospitalization for unstable angina)
60 months
SPIRE-2NCT01975389 Bococizumab n = 9000; high risk of CVD event;
background lipid-lowering treatment;
LDL-C ≥100 mg/dL or non-HDL-C
≥130 mg/dL
Time to composite major cardiovascular
event (cardiovascular death, non-fatal
myocardial infarction, non-fatal stroke,
and hospitalization for unstable angina)
60 months
CVD Cardiovascular disease, HDL-C High-density lipoprotein cholesterol, LDL-C Low-density lipoprotein cholesterol
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12-week proof of concept, randomized controlled trial
during including 50 homozygous FH patients, but only
in those carrying alleles of the LDL-receptor with some
residual activity, as can be expected from the mechanism
of action of PCSK9 inhibition (Fig. 1) [38]. Similarly,
despite the potency of statins, only a minority of patients
with heterozygous FH attain optimal cholesterol levels
and considerable excess mortality still exists [11, 39].
Published trials of PCSK9 inhibitors have already dem-
onstrated the potential to reach unprecedented low
LDL-C levels in heterozygous FH and currently ongoing
clinical outcome studies will establish whether addition
of PCSK9 inhibition to current treatment confers sus-
tained clinical benefit in this patient population (NCT
Trial Identifier: NCT01968980) [40–42].
All of the four ongoing clinical outcome trials on
PCSK9-inhibition antibodies include high-risk patients
(either clinically manifest CVD or dyslipidemia) and will
determine the efficacy of PCSK9 inhibitors added to
lipid-lowering therapy in reducing major CVD event
rates compared to placebo over approximately 5 years of
follow-up (Table 1). The first results of these trials are
expected in 2018. Ultimately, the societal benefit of these
treatments will depend on their costs, safety, and effi-
cacy. The expected high cost of PCSK9 inhibitors could
indicate that their use may only be cost-effective in the
treatment of patients with a particularly high baseline
risk; a crucial challenge will be defining the level of base-
line risk at which PCSK9 inhibition is valuable. The bene-
fit of PCSK9 inhibition in practice will further depend on
therapy compliance and therefore dose and frequency of
administration need to be carefully considered. Finally,
despite the fact that ongoing phase III trials will determine
the safety of PCSK9 inhibition after 5 years of follow-up,
post-marketing registration and extended follow-up stud-
ies are required to confirm their safety in the longer term.
Conclusions
Merely a decade after the discovery of the essential role
of PCSK9 in LDL-C metabolism, its inhibition has
emerged as one of the most promising novel strategies
to reduce CVD. Their remarkable efficacy in reducing
LDL-C and the possible synergistic effects with statins,
combined with a favorable safety profile and tolerability,
provide these drugs with the potential to revolutionize
the treatment of patients at high risk of CVD. Ongoing
clinical outcome trials will provide a definite answer to
the question on the clinical benefit of further reducing
LDL-C. Irrespective of their results, the rapid develop-
ment of these drugs illustrates the possibilities offered
by new technologies and genetic research methods.
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